ng/ml

2
IL-8 Secretion by O A FLS Stim ulated w ith IFN - orIL-17 0 5000 10000 15000 20000 25000 FLS A lone IFN 0.5 IFN 5 IFN 50 IL-17 0.1 IL-17 1 IL-17 10 pg/ml IL-6 Secretion by O A FLS Stim ulated w ith IFN - g orIL-17 0 10000 20000 30000 40000 50000 60000 70000 80000 90000 FLS A lone IFN 0.5 IFN 5 IFN 50 IL-17 0.1 IL-17 1 IL-17 10 pg/ml ** ng/ml ng/ml IL-8 Secretion by O A FLS Stim ulated w ith IFN - orIL-17 0 5000 10000 15000 20000 25000 FLS A lone IFN 0.5 IFN 5 IFN 50 IL-17 0.1 IL-17 1 IL-17 10 pg/ml IL-6 Secretion by O A FLS Stim ulated w ith IFN - g orIL-17 0 10000 20000 30000 40000 50000 60000 70000 80000 90000 FLS A lone IFN 0.5 IFN 5 IFN 50 IL-17 0.1 IL-17 1 IL-17 10 pg/ml gure 2 Panel A

description

Figure 2 Panel A. **. *. ng/ml. **. **. **. **. **. ng/ml. Figure 2 Panel B. *. *. *. *. *. ng/ml. *. *. *. *. *. *. ng/ml. - PowerPoint PPT Presentation

Transcript of ng/ml

Page 1: ng/ml

IL-8 Secretion by OA FLS Stimulated with IFN- or IL-17

0

5000

10000

15000

20000

25000

FLSAlone

IFN 0.5 IFN 5 IFN 50 IL-17 0.1 IL-17 1 IL-17 10

pg

/ml

IL-6 Secretion by OA FLS Stimulated with IFN-g or IL-17

0

10000

20000

30000

40000

50000

60000

70000

80000

90000

FLSAlone

IFN 0.5 IFN 5 IFN 50 IL-17 0.1 IL-17 1 IL-17 10

pg

/ml

*

**

******

**

**

ng/ml

ng/ml

IL-8 Secretion by OA FLS Stimulated with IFN- or IL-17

0

5000

10000

15000

20000

25000

FLSAlone

IFN 0.5 IFN 5 IFN 50 IL-17 0.1 IL-17 1 IL-17 10

pg

/ml

IL-6 Secretion by OA FLS Stimulated with IFN-g or IL-17

0

10000

20000

30000

40000

50000

60000

70000

80000

90000

FLSAlone

IFN 0.5 IFN 5 IFN 50 IL-17 0.1 IL-17 1 IL-17 10

pg

/ml

Figure 2 Panel A

Page 2: ng/ml

IL-6 Secretion by OA FLS Stimulated with IFN-g or IL-17

0

10000

20000

30000

40000

50000

60000

70000

FLS only IFN 0.5 IFN 5 IFN 50 IL-17 1 IL-17 10 IL-17 100

pg/m

l

IL-8 Secretion by OA FLS Stimulated with IFN-g or IL-17

0

2000

4000

6000

8000

10000

12000

14000

FLS only IFN 0.5 IFN 5 IFN 50 IL-17 1 IL-17 10 IL-17 100

pg/m

l

ng/ml

ng/ml

*

*

**

*

*

*

***

*

Figure 2 Panel B


Asociación Bioquímica de Mendoza - TUMOR …...testosterona hombre 20-40 años vr: 2,49-8,36 ng/ml. 0,03 ng/ml h´ myor de 50 años: 1,93-7,40 ng/ml. amar claro amarillo amar claro

Asociación Bioquímica de Mendoza - TUMOR …...testosterona hombre 20-40 años vr: 2,49-8,36 ng/ml. 0,03 ng/ml h´ myor de 50 años: 1,93-7,40 ng/ml. amar claro amarillo amar claro

UNIVERSIDADE FEDERAL DE UBERLÂNDIA Instituto de …...61,7 ng/mL, 38,0 ng/mL no câncer de mama inicial e 34,2 ng/mL no câncer de mama metastático. O melhor valor de cutoff foi

UNIVERSIDADE FEDERAL DE UBERLÂNDIA Instituto de …...61,7 ng/mL, 38,0 ng/mL no câncer de mama inicial e 34,2 ng/mL no câncer de mama metastático. O melhor valor de cutoff foi

Ganglioside GM1 theTrk receptor - PNAScontrol, 0; NGF(1 ng/ml), 1 ± 0.3; NGF(50ng/ml), 33 ± 2.7; NGF(1 ng/ml) +GM1,46 + 3.1; NGF(50ng/ml) +GM1,78 ±4.3; andGM1 alone, 0 (mean ±

Ganglioside GM1 theTrk receptor - PNAScontrol, 0; NGF(1 ng/ml), 1 ± 0.3; NGF(50ng/ml), 33 ± 2.7; NGF(1 ng/ml) +GM1,46 + 3.1; NGF(50ng/ml) +GM1,78 ±4.3; andGM1 alone, 0 (mean ±

9. Vitamine D et diabète - sfndt.org · PTH (pg/mL) 25OH D (ng/mL) P

9. Vitamine D et diabète - sfndt.org · PTH (pg/mL) 25OH D (ng/mL) P

ACPP: ANSELL CYTOSTATIC PERMEATION PROGRAM 13 Vinorelbine Navelbine Pierre Fabre LCMS/MS 10 mg/ml 6,48 ng/ml 43,72 ng/ml. SURGICAL GLOVES GAMMEX® Non-Latex GAMMEX® Latex GAMMEX®

ACPP: ANSELL CYTOSTATIC PERMEATION PROGRAM 13 Vinorelbine Navelbine Pierre Fabre LCMS/MS 10 mg/ml 6,48 ng/ml 43,72 ng/ml. SURGICAL GLOVES GAMMEX® Non-Latex GAMMEX® Latex GAMMEX®

Aspects pharmacologiques des - AEI › ... › 2012 › workshop › Solas-Pharmaco.pdf · En pratique: Cmin ~ 1100-2690 ng/ml (moyenne: 2030 ng/ml) >> CI 99 • 74% RVS (phase 2)

Aspects pharmacologiques des - AEI › ... › 2012 › workshop › Solas-Pharmaco.pdf · En pratique: Cmin ~ 1100-2690 ng/ml (moyenne: 2030 ng/ml) >> CI 99 • 74% RVS (phase 2)

CompostosAzólicosnaDoençade Chagas: situaçãoatual · AtividadeComparativa In vitro • Ravuconazol – MIC 300 nM(221 ng/ml) para formas epimastigotas – MIC 1 nM (7.4 ng/ml)

CompostosAzólicosnaDoençade Chagas: situaçãoatual · AtividadeComparativa In vitro • Ravuconazol – MIC 300 nM(221 ng/ml) para formas epimastigotas – MIC 1 nM (7.4 ng/ml)

· PDF fileMicro-nanosisteme pentru aplicatii biomedicale BIO-MEMS ... 1 100 ng/mL (2 — 6 ng/mL valori ... 30 minute 16 h PotentlaI(mV)

· PDF fileMicro-nanosisteme pentru aplicatii biomedicale BIO-MEMS ... 1 100 ng/mL (2 — 6 ng/mL valori ... 30 minute 16 h PotentlaI(mV)

Application Note: Enhanced proliferation of primary NSCs and ......Day 10 ng/mL HS bFGF, every 48 hr 10 ng/mL native bFGF, daily (positive control) 10 ng/mL native bFGF, every 48 hr

Application Note: Enhanced proliferation of primary NSCs and ......Day 10 ng/mL HS bFGF, every 48 hr 10 ng/mL native bFGF, daily (positive control) 10 ng/mL native bFGF, every 48 hr

Corning® ™ BioCoat 癌細胞浸潤アッセイシステム...100 80 60 40 20 0 0 0.1 ng/mL 1.0 ng/mL 10 ng/mL BioCoat アンジオジェネシス： 血管内皮細胞浸潤アッセイシステム

Corning® ™ BioCoat 癌細胞浸潤アッセイシステム...100 80 60 40 20 0 0 0.1 ng/mL 1.0 ng/mL 10 ng/mL BioCoat アンジオジェネシス： 血管内皮細胞浸潤アッセイシステム

Sclerosi sistemica con compromissione cardiopolmonare avanzata · ng/mL, valori normali 1.4-5.7 ng/mL), Ca 15.3 (> 250 U.O. di Medicina Interna ad Orientamento Immunologico (Direttore:

Sclerosi sistemica con compromissione cardiopolmonare avanzata · ng/mL, valori normali 1.4-5.7 ng/mL), Ca 15.3 (> 250 U.O. di Medicina Interna ad Orientamento Immunologico (Direttore:

Research Paper Development and Validation of a Serum ... · OD of 450 nm. For Intra-assay Precision: CHI3L1, CV: 5.2% (0.25 ng/ml) and CV: 3.6% (2 ng/ml); MMP13, 4.9% (2 ng/ml) and

Research Paper Development and Validation of a Serum ... · OD of 450 nm. For Intra-assay Precision: CHI3L1, CV: 5.2% (0.25 ng/ml) and CV: 3.6% (2 ng/ml); MMP13, 4.9% (2 ng/ml) and

Solving Poison Control Center Intoxication Cases Using ... · MDA MDE Serum, 2/20 87 ng/mL 18.82 ng/mL 61 ng/mL Serum, 2/26 ND ND ND Urine, 2/22 395 ng/mL 123.3 ng/mL 46 ng/mL Green

Solving Poison Control Center Intoxication Cases Using ... · MDA MDE Serum, 2/20 87 ng/mL 18.82 ng/mL 61 ng/mL Serum, 2/26 ND ND ND Urine, 2/22 395 ng/mL 123.3 ng/mL 46 ng/mL Green

The Influence of Porcine and Axolotl ECM Factors on Human ... · Insoluble Axolotl 5 µg/mL Insoluble Axolotl 500 ng/mL Soluble Axolotl 5 µg/mL Soluble Axolotl 500 ng/mL Figure

The Influence of Porcine and Axolotl ECM Factors on Human ... · Insoluble Axolotl 5 µg/mL Insoluble Axolotl 500 ng/mL Soluble Axolotl 5 µg/mL Soluble Axolotl 500 ng/mL Figure

Clearing Up The Confusion About Substance Abuse …...2018/02/04  · 500 ng/mL Amphetamine Methamphetamine 250 ng/mL. 250 ng/mL. MDMA4/MDA5 500 ng/mL MDMA MDA 250 ng/mL. 250 ng/mL.

Clearing Up The Confusion About Substance Abuse …...2018/02/04  · 500 ng/mL Amphetamine Methamphetamine 250 ng/mL. 250 ng/mL. MDMA4/MDA5 500 ng/mL MDMA MDA 250 ng/mL. 250 ng/mL.

Le courrier de la biologie médicale - Synlab · de la biologie médicale Le courrier de la biologie médicale / info dosage vitamine D 80 ng/mL 30 ng/mL 10 ng/mL 200 nmol/L 75 nmol/L

Le courrier de la biologie médicale - Synlab · de la biologie médicale Le courrier de la biologie médicale / info dosage vitamine D 80 ng/mL 30 ng/mL 10 ng/mL 200 nmol/L 75 nmol/L

Development of a UPLC-MS/MS Method for the Determination ......0.150/2.50 ng/mL 1.00/2.50 ng/mL 8.00/2.50 ng/mL % Recovery 80.3 86.6 87.5 Mean % Recovery 84.8 IS Normalized Matrix

Development of a UPLC-MS/MS Method for the Determination ......0.150/2.50 ng/mL 1.00/2.50 ng/mL 8.00/2.50 ng/mL % Recovery 80.3 86.6 87.5 Mean % Recovery 84.8 IS Normalized Matrix

Oral Fluid Drug Screen Device - Andatechdocuments.andatech.com.au/manuals/oratect-iii-saliva-drug-testing-k… · Diazepam 25 ng/ml 40 ng/ml 20 ng/ml 25 ng/ml 10 ng/ml 5 ng/ml 1.

Oral Fluid Drug Screen Device - Andatechdocuments.andatech.com.au/manuals/oratect-iii-saliva-drug-testing-k… · Diazepam 25 ng/ml 40 ng/ml 20 ng/ml 25 ng/ml 10 ng/ml 5 ng/ml 1.

Wybrane substancje: znaczenie dla organizmu oraz możliwe ...bc.wydawnictwo-tygiel.pl/public/assets/7/Wybrane substancje MO.pdf · zimowe >38 ng/ml vs < 38 ng/ml Ryzykowe względne

Wybrane substancje: znaczenie dla organizmu oraz możliwe ...bc.wydawnictwo-tygiel.pl/public/assets/7/Wybrane substancje MO.pdf · zimowe >38 ng/ml vs < 38 ng/ml Ryzykowe względne

Applications - Eppendorf · buffer). The wells thus contained the following final DNA concentrations: 25 ng/ml, 10 ng/ml, 2.5 ng/ml, 500 pg/ml, Results and Discussion Based on the

Applications - Eppendorf · buffer). The wells thus contained the following final DNA concentrations: 25 ng/ml, 10 ng/ml, 2.5 ng/ml, 500 pg/ml, Results and Discussion Based on the